White Paper

Simple Western Advances Cutting-Edge Duchenne Muscular Dystrophy Research

Source: bio-techne
Bio-Techne 1
FIGURE 1. Schematic of dystrophin connecting the actin network to the transmembrane components of the DGC. In individuals with DMD, dystrophin is missing or made in very small amounts, which damages muscle tissue and ultimately leads to death by early adulthood.

Duchenne Muscular Dystrophy (DMD) is a severe genetic disease characterized by the progressive breakdown of skeletal and cardiac muscles, resulting in weakness, loss of cardiac function and premature death. The cause of DMD is frameshift mutations to dystrophin, a gene responsible for linking the actin network to transmembrane components of the dystrophin-associated glycoprotein complex (DGC). These mutations result in strong reduction or complete absence of functional dystrophin. While recent advancements in gene editing therapies are offering hope of restoring dystrophin function in human cells, reliable detection and quantification of dystrophin remains a challenge. As one of the largest proteins in the human body (427 kDa), its extreme molecular weight makes dystrophin very difficult to reliably detect, let alone quantify, with traditional techinques like Western blot.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online